Cargando…
Global Registries in Congenital Hyperinsulinism
Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatm...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201947/ https://www.ncbi.nlm.nih.gov/pubmed/35721728 http://dx.doi.org/10.3389/fendo.2022.876903 |
_version_ | 1784728426181033984 |
---|---|
author | Pasquini, Tai L. S. Mesfin, Mahlet Schmitt, Jennifer Raskin, Julie |
author_facet | Pasquini, Tai L. S. Mesfin, Mahlet Schmitt, Jennifer Raskin, Julie |
author_sort | Pasquini, Tai L. S. |
collection | PubMed |
description | Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatments, and identifying and managing hypoglycemia before it is prolonged and causes brain damage or death. Patient-reported data provides a basis for understanding the day-to-day experience of living with HI. Commonly identified goals of registries include performing natural history studies, establishing a network for future product and treatment studies, and supporting patients and families to offer more successful and coordinated care. Congenital Hyperinsulinism International (CHI) created the HI Global Registry (HIGR) in October 2018 as the first global patient-powered hyperinsulinism registry. The registry consists of thirteen surveys made up of questions about the patient’s experience with HI over their lifetime. An international team of HI experts, including family members of children with HI, advocates, clinicians, and researchers, developed the survey questions. HIGR is managed by CHI and advised by internationally recognized HI patient advocates and experts. This paper aims to characterize HI through the experience of individuals who live with it. This paper includes descriptive statistics on the birthing experience, hospitalizations, medication management, feeding challenges, experiences with glucose monitoring devices, and the overall disease burden to provide insights into the current data in HIGR and demonstrate the potential areas of future research. As of January 2022, 344 respondents from 37 countries consented to participate in HIGR. Parents or guardians of individuals living with HI represented 83.9% of the respondents, 15.3% were individuals living with HI. Data from HIGR has already provided insight into access challenges, patients’ and caregivers’ quality of life, and to inform clinical trial research programs. Data is also available to researchers seeking to study the pathophysiology of HI retrospectively or to design prospective trials related to improving HI patient outcomes. Understanding the natural history of the disease can also guide standards of care. The data generated through HIGR provides an opportunity to improve the lives of all those affected by HI. |
format | Online Article Text |
id | pubmed-9201947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92019472022-06-17 Global Registries in Congenital Hyperinsulinism Pasquini, Tai L. S. Mesfin, Mahlet Schmitt, Jennifer Raskin, Julie Front Endocrinol (Lausanne) Endocrinology Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatments, and identifying and managing hypoglycemia before it is prolonged and causes brain damage or death. Patient-reported data provides a basis for understanding the day-to-day experience of living with HI. Commonly identified goals of registries include performing natural history studies, establishing a network for future product and treatment studies, and supporting patients and families to offer more successful and coordinated care. Congenital Hyperinsulinism International (CHI) created the HI Global Registry (HIGR) in October 2018 as the first global patient-powered hyperinsulinism registry. The registry consists of thirteen surveys made up of questions about the patient’s experience with HI over their lifetime. An international team of HI experts, including family members of children with HI, advocates, clinicians, and researchers, developed the survey questions. HIGR is managed by CHI and advised by internationally recognized HI patient advocates and experts. This paper aims to characterize HI through the experience of individuals who live with it. This paper includes descriptive statistics on the birthing experience, hospitalizations, medication management, feeding challenges, experiences with glucose monitoring devices, and the overall disease burden to provide insights into the current data in HIGR and demonstrate the potential areas of future research. As of January 2022, 344 respondents from 37 countries consented to participate in HIGR. Parents or guardians of individuals living with HI represented 83.9% of the respondents, 15.3% were individuals living with HI. Data from HIGR has already provided insight into access challenges, patients’ and caregivers’ quality of life, and to inform clinical trial research programs. Data is also available to researchers seeking to study the pathophysiology of HI retrospectively or to design prospective trials related to improving HI patient outcomes. Understanding the natural history of the disease can also guide standards of care. The data generated through HIGR provides an opportunity to improve the lives of all those affected by HI. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9201947/ /pubmed/35721728 http://dx.doi.org/10.3389/fendo.2022.876903 Text en Copyright © 2022 Pasquini, Mesfin, Schmitt and Raskin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Pasquini, Tai L. S. Mesfin, Mahlet Schmitt, Jennifer Raskin, Julie Global Registries in Congenital Hyperinsulinism |
title | Global Registries in Congenital Hyperinsulinism |
title_full | Global Registries in Congenital Hyperinsulinism |
title_fullStr | Global Registries in Congenital Hyperinsulinism |
title_full_unstemmed | Global Registries in Congenital Hyperinsulinism |
title_short | Global Registries in Congenital Hyperinsulinism |
title_sort | global registries in congenital hyperinsulinism |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201947/ https://www.ncbi.nlm.nih.gov/pubmed/35721728 http://dx.doi.org/10.3389/fendo.2022.876903 |
work_keys_str_mv | AT pasquinitails globalregistriesincongenitalhyperinsulinism AT mesfinmahlet globalregistriesincongenitalhyperinsulinism AT schmittjennifer globalregistriesincongenitalhyperinsulinism AT raskinjulie globalregistriesincongenitalhyperinsulinism |